Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (15)

2022

  1. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  2. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

    Journal of Hepatology, Vol. 76, Núm. 4, pp. 812-821

  3. Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study

    Liver Transplantation, Vol. 28, Núm. 7, pp. 1257-1261

2021

  1. Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 11, pp. 780-786

  2. Overview of virus and cancer relationships. Position paper

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555

2020

  1. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis

    Hepatology, Vol. 72, Núm. 6, pp. 1924-1934

  2. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

    The Journal of infectious diseases, Vol. 222, Núm. 5, pp. 726-733

2019

  1. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  2. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Liver Transplantation for Hepatic Trauma: A Study from the European Liver Transplant Registry

    Transplantation, Vol. 100, Núm. 11, pp. 2372-2381

2015

  1. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2011

  1. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large multicenter cohort study

    Transplantation, Vol. 92, Núm. 3, pp. 334-340